ZIOPHARM Oncology, Inc. Forecast, price target & analysts
ZIOPHARM Oncology, Inc. Target price 2025 - Analyst rating & recommendation
ZIOPHARM Oncology, Inc. Classifications & Recommendation:
ZIOPHARM Oncology, Inc. Price Target
| Target Price | $3.06 |
| Price | $2.31 |
| Potential |
32.47%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target ZIOPHARM Oncology, Inc. 2026 .
The average ZIOPHARM Oncology, Inc. target price is $3.06.
This is
32.47%
register free of charge
$7.88
240.91%
register free of charge
$1.52
34.42%
register free of charge
|
|
| A rating was issued by 6 analysts: 0 Analysts recommend ZIOPHARM Oncology, Inc. to buy, 3 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ZIOPHARM Oncology, Inc. stock has an average upside potential 2026 of
32.47%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.01 | 568.06 |
| 0.00% | 5,680,500.00% | |
| Net Margin | -46,800.00% | 0.32% |
| 86.68% | 100.00% |
4 Analysts have issued a sales forecast ZIOPHARM Oncology, Inc. 2025 . The average ZIOPHARM Oncology, Inc. sales estimate is
This results in the following potential growth metrics:
4 ZIOPHARM Oncology, Inc. Analysts have issued a net profit forecast 2025. The average ZIOPHARM Oncology, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2024 | -46,800.00% | 86.68% |
|---|---|---|
| 2025 |
0.32%
100.00%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.92 | 0.88 |
| 32.73% | 130.14% | |
| P/E | 2.63 | |
| EV/Sales | 0.00 |
4 Analysts have issued a ZIOPHARM Oncology, Inc. forecast for earnings per share. The average ZIOPHARM Oncology, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the ZIOPHARM Oncology, Inc. stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 221.52 | 56.55% |
|---|---|---|
| 2025 |
0.00
100.00%
Unlock
|
|
P/S ratio
| Current | 509.52 | 31.49% |
|---|---|---|
| 2025 |
0.01
100.00%
Unlock
|
|
ZIOPHARM Oncology, Inc....
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
